SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LAB

Standard Biotools Inc. (NASDAQ:LAB)

US · Delayed Price · Currency is USD
Also listed: FLDMHealthcare · Medical - Specialties
$0.63+$0.02 (+2.82%)
 
Market cap
$249M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 10, 2011
Market Cap$249.11M-55.6%
Revenue (ttm)$84.43M-22.0%
Net Income-$39.21M+69.4%
EPS-$0.11+67.7%
Shares Out394.79M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,808,206
Open$0.62
Previous Close$0.61
Day's Range$0.57 - $0.64
52-Week Range$0.39 - $1.72
Beta1.35
AnalystsBuy
Price Target$3.25(+415.06%)
Earnings DateMar 3, 2027

About LAB

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Address
50 Milk Street, Boston, MA, 02109, US
Market Cap
249 million
Employees
387
Industrial Classification
Medical - Specialties

Standard Biotools Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
52nd Percentile Overall Score
LAB InsiderScore:68 / 99

Standard Biotools Inc. scored higher than 52% of companies evaluated by InsiderBuying, and ranked 39th out of 108 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Standard Biotools Inc. bought $46.9K of stock across 1 purchase in the last 90 days, the largest of them $46.9K.

Stake Increase

The average purchase added about 22% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$46.90K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From LAB’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+2.82%
5 Days
-9.99%
1 Month
-0.72%
6 Months
-38.74%
1 Year
-55.56%

$LAB stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LAB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LAB's directors and management

Net Shares Purchased by Insiders−80k−40k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LAB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

LAB Revenue by Segment or Geography

LAB's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New LAB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LAB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in LAB

VTIVanguard Morningstar Total Stock Market ETF$4.17M
VXFVanguard Extended Market ETF$2.15M
IBBiShares Biotechnology ETF$1.79M
SCHASchwab U.S. Small-Cap ETF$886.30K
VHTVanguard Health Care ETF$418.69K
GNOMGlobal X - Genomics & Biotechnology ETF$401.20K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from LAB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
54.22
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$46.90K
Distinct Buyers
1

Insider Score Trend Over Time

-12.3 since Nov 6
0255075100Nov 6 — Insider Score 80.1Nov 7 — Insider Score 80.0Nov 8 — Insider Score 80.2Nov 9 — Insider Score 80.3Nov 10 — Insider Score 78.7Nov 11 — Insider Score 78.4Nov 12 — Insider Score 77.6Nov 13 — Insider Score 76.6Nov 14 — Insider Score 74.9Nov 15 — Insider Score 75.5Nov 16 — Insider Score 75.3Nov 17 — Insider Score 72.9Nov 18 — Insider Score 71.4Nov 19 — Insider Score 70.8Nov 20 — Insider Score 68.3Nov 21 — Insider Score 67.5Nov 22 — Insider Score 67.8Nov 6Nov 14Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

GNOMGlobal X - Genomics & Biotechnology ETF0.15%
IBBiShares Biotechnology ETF0.02%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.